Search Result

Results for "

Liver injury

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (3) 17β-HSD (56) 5-HT Receptor (3) Acetyl-CoA Carboxylase (1) Acyltransferase (1) Adrenergic Receptor (4) Akt (25) Aldehyde Dehydrogenase (ALDH) (1) Aldose Reductase (1) Aminopeptidase (1) Aminotransferases (Transaminases) (10) AMPK (22) Amyloid-β (3) Anaplastic lymphoma kinase (ALK) (3) Androgen Receptor (1) Antibiotic (9) AP-1 (1) Apical Sodium-Dependent Bile Acid Transporter (5) Apoptosis (61) Arginase (2) ASK1 (1) Atg8/LC3 (1) Autophagy (27) Bacterial (21) Bcl-2 Family (10) Beta-secretase (1) Biochemical Assay Reagents (3) c-Fms (1) c-Myc (2) Calcium Channel (2) CaMK (1) Carnitine Palmitoyltransferase (CPT) (3) Caspase (17) CaSR (2) Cathepsin (1) CDK (6) Cholinesterase (ChE) (4) Collagen (1) COX (12) Cuproptosis (1) CXCR (2) Cyclic GMP-AMP Synthase (1) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (3) Cytochrome P450 (11) Dengue Virus (6) Deubiquitinase (1) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (8) Dopamine Receptor (3) Drug Derivative (9) Drug Intermediate (1) Drug Metabolite (4) DUBTACs (1) DYRK (1) E1/E2/E3 Enzyme (2) Elastase (1) Endogenous Metabolite (18) Endothelin Receptor (1) Environmental Pollutants (3) Epigenetic Reader Domain (2) ER-phagy (1) ERK (13) Estrogen Receptor/ERR (2) FABP (1) Factor Xa (2) Fatty Acid Synthase (FASN) (2) Fc Receptor (FcR) (1) Ferroptosis (20) Flavivirus (6) Fluorescent Dye (7) FOXO (1) Free Fatty Acid Receptor (1) Fungal (8) FXR (11) G protein-coupled Bile Acid Receptor 1 (1) G Protein-coupled Receptor Kinase (GRK) (1) Galectin (1) GLUT (1) Glutathione Peroxidase (2) Glutathione S-transferase (1) Glycosidase (2) GSK-3 (6) HBV (3) HCV (2) HCV Protease (1) HDAC (2) Heme Oxygenase (HO) (5) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (3) Histone Acetyltransferase (1) HIV (2) HSP (2) HSV (2) IKK (2) Influenza Virus (2) Insecticide (2) Interleukin Related (36) IRE1 (1) Isotope-Labeled Compounds (13) JAK (8) JNK (19) Keap1-Nrf2 (24) Lactate Dehydrogenase (6) LDLR (2) Leukotriene Receptor (8) Ligands for E3 Ligase (1) Lipoxygenase (3) LPL Receptor (2) LRRK2 (2) MAP3K (2) MDM-2/p53 (3) MEK (2) Microtubule/Tubulin (4) Mitochondrial Metabolism (2) Mitophagy (7) Mixed Lineage Kinase (2) MMP (5) Monoamine Oxidase (3) mTOR (10) NADPH Oxidase (1) Necroptosis (2) NF-κB (49) NO Synthase (11) NOD-like Receptor (NLR) (12) Nuclear Factor of activated T Cells (NFAT) (1) Nuclear Hormone Receptor 4A/NR4A (4) Nucleoside Antimetabolite/Analog (1) Osteopontin (1) P-glycoprotein (1) p38 MAPK (23) p62 (1) PAK (2) Parasite (7) PARP (7) PCSK9 (1) PDGFR (1) PERK (2) PGE synthase (3) Phosphatase (3) Phosphodiesterase (PDE) (2) Phospholipase (1) PI3K (16) PIN1 (1) PKA (1) PPAR (9) Prostaglandin Receptor (1) PROTACs (2) Pyroptosis (5) Quinone Reductase (2) RANKL/RANK (1) Reactive Oxygen Species (ROS) (39) Reference Standards (34) RIP kinase (7) SARS-CoV (1) Sirtuin (11) SOD (8) Src (2) STAT (11) Stearoyl-CoA Desaturase (SCD) (1) STING (3) Survivin (1) TGF-beta/Smad (3) TGF-β Receptor (1) Thrombin (2) TNF Receptor (19) TNK1 (2) Toll-like Receptor (TLR) (5) TREM receptor (2) UGT (1) URAT1 (1) VEGFR (4) Wnt (3) β-catenin (5) β-glucuronidase (1)
By Research Areas:	Cancer (69) Cardiovascular Disease (43) Endocrinology (6) Infection (48) Inflammation/Immunology (142) Metabolic Disease (190) Neurological Disease (49)
Oligonucleotides:	Solvents (1) Preservatives (1) Aptamers (1)

326

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

113

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Montelukast sodium 10+ Cited Publications MK0476	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

Odevixibat 4 Publications Verification A4250	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

Montelukast 10+ Cited Publications MK0476 free base	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

Geniposidic acid 5+ Cited Publications	FXR Sirtuin TNF Receptor Interleukin Related	Metabolic Disease
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .

Nangibotide TFA Maximum Cited Publications 7 Publications Verification LR12 TFA	TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis	Cardiovascular Disease Inflammation/Immunology
Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .

Gypenoside XLIX 2 Publications Verification	PPAR Sirtuin Keap1-Nrf2 Toll-like Receptor (TLR) NF-κB Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Pyroptosis Autophagy	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a K_a value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .

Propacetamol hydrochloride	NF-κB	Neurological Disease Cancer
Propacetamol hydrochloride is an orally active prodrug of paracetamol and an inducer of acute liver injury models, with multiple properties including antinociception, antioxidation and gastroprotection. Propacetamol hydrochloride potentiates Tramadol and attenuates Aspirin (HY-14654)-induced gastric mucosal damage and lipid peroxidation. Under specific conditions, Propacetamol hydrochloride also acts as a hepatotoxic inducer, triggering acute liver injury, oxidative stress and apoptosis, with strain differences in toxicity sensitivity. Propacetamol hydrochloride can be used in the research of acute liver injury, drug-induced hepatotoxicity and gastric mucosal damage .

CAY10594 1 Publications Verification	Phospholipase Apoptosis GSK-3 Anaplastic lymphoma kinase (ALK) STAT Interleukin Related G Protein-coupled Receptor Kinase (GRK) CXCR Lactate Dehydrogenase	Inflammation/Immunology Cancer
CAY10594 is an orally active PLD2 inhibitor with an IC₅₀ of 140 nM. CAY10594 has activities such as anti-tumor, anti-oxidation and liver protection. CAY10594 can be used for the research of diseases like breast cancer, acute liver injury and colitis .

Graveoline Rutamine	Apoptosis Autophagy Fungal Parasite Reactive Oxygen Species (ROS) Interleukin Related JAK STAT	Infection Inflammation/Immunology Cancer
Graveoline (Rutamine) is an orally active alkaloid with various activities such as antifungal, antiparasitic, anti-inflammatory, and antitumor effects. Graveoline can induce tumor cell apoptosis and autophagy through a reactive oxygen species-mediated pathway. Graveoline has an MIC of 500 μg/mL for Candida albicans. Graveoline can be used in the research of various diseases such as tumors and liver injury .

Rehmannioside D 1 Publications Verification	Sirtuin Apoptosis MDM-2/p53 Reactive Oxygen Species (ROS) Bcl-2 Family Caspase	Metabolic Disease Inflammation/Immunology
Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis .

XT2 2 Publications Verification	NF-κB	Inflammation/Immunology
XT2 is a potent, orally active, and selective inhibitor of NF-κB-inducing kinase (NIK) with an IC₅₀ of 9.1 nM. XT2 suppresses CCl4-induced upregulation of ALT, a key biomarker of acute liver injury. XT2 also decreases immune cell infiltration into the injured liver tissue. XT2 has the potential for the research of liver inflammatory diseases . XT2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Sorbitol dehydrogenase L-Iditol dehydrogenase; Polyol dehydrogenase; SDH	Biochemical Assay Reagents	Metabolic Disease
Sorbitol dehydrogenase (L-Iditol dehydrogenase) is an oxidoreductasea and catalyses the conversion of sorbitol to fructose with NAD ⁺ as the coenzyme. Sorbitol dehydrogenase catalyses pH-dependent redox reactions between NAD ⁺/NADH and sorbitol/fructose. Sorbitol dehydrogenase is implicated in diabetic complications and is a biomarker of drug-induced liver injury. Sorbitol dehydrogenase can be used for the research of diabetes and liver injury .

Ganosporeric acid A	Others	Others
Ganosporeric acid A, a natural product, is isolated from the ether-soluble fraction of the spores of Ganoderma lucidum. Ganosporeric acid A can be used for the research of liver injury .

Homopterocarpin (-)-Homopterocarpin; 3,9-Dimethoxypterocarpan	Monoamine Oxidase Parasite	Inflammation/Immunology
Homopterocarpin is an isoflavonoid that can be isolated from Pterocarpus erinaceus. Homopterocarpin has hepatoprotective, antioxidant and antiplasmodial activity. Homopterocarpin is a competitive reversible inhibitor of human monoamine oxidase-B with an IC₅₀ and a K_i of 0.72 and 0.21 μM for hMAO-B, respectively. Homopterocarpin can be used for the research of liver injury and oxidative stress .

DI-1548	E1/E2/E3 Enzyme Keap1-Nrf2	Metabolic Disease
DI-1548 is a potent, selective, and irreversible covalent inhibitor of DCN1 (IC₅₀ = 4.6 nM). DI-1548 potently and selectively inhibits cullin 3 neddylation at nanomolar concentrations, and exhibits no obvious effect on the neddylation of other cullin members (including cullin 1, 2, 4A, 4B, and 5). DI-1548 exhibits no cytotoxicity. DI-1548 covalently binds to DCN1, disrupting the DCN1-UBC12 interaction, causing the collapse of the neddylation complex, inactivating CRL3, leading to NRF2 accumulation and upregulation of its target genes, and ultimately protecting mice from liver damage. DI-1548 can be used in liver injury research .

Notoginsenoside D	Others	Metabolic Disease
Notoginsenoside D is a dammarane-type triterpene oligoglycoside. Notoginsenoside D can be isolated from the dried roots of Panax notoginseng (BURK.) F. H. CHEN. Notoginsenoside D can be used in the research of liver injury .

3,4-Didehydroglabridin	Others	Inflammation/Immunology
3,4-Didehydroglabridin is a natural product that can be found in licorice. 3,4-Didehydroglabridin exhibits protective activities against carbon tetrachloride-induced HepG2 cells injury. 3,4-Didehydroglabridin has the potential for the research of liver injury .

Galectin-3-IN-6	Galectin	Cardiovascular Disease Inflammation/Immunology Cancer
Galectin-3-IN-6 is a human and murine galectin-3 (Gal-3) inhibitor, with an IC₅₀ of 12 nM against human galectin-3, an IC₅₀ of 12.6 nM against mutant murine galectin-3 (V160A), and a K_d of 13 nM for human galectin-3, as well as oral bioavailability. Galectin-3-IN-6 reduces the levels of liver fibrosis markers type I collagen and α-smooth muscle actin in mouse models of acute liver injury and fibrosis. Galectin-3-IN-6 can be used for the research of acute liver injury and fibrosis .

BET-IN-13	Epigenetic Reader Domain	Inflammation/Immunology
BET-IN-13 is a potent BET inhibitor with an IC₅₀ value of 1.6 nM. BET-IN-13 reduces LPS-induced TNF-α, IL-1β, IL-6, and NOS2 mRNA expression levels. BET-IN-13 shows anti-inflammatory activity. BET-IN-13 has the potential for the research of acute liver injury .

Montelukast dicyclohexylamine MK0476 dicyclohexylamine	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .

Montelukast (Standard) MK0476 free base (Standard)	Reference Standards Leukotriene Receptor	Inflammation/Immunology
Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

RIP1-IN-1	RIP kinase Necroptosis	Inflammation/Immunology
RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (K_d: 110 nM). RIP1-IN-1 exhibits strong anti-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury .

Colchiceine O10-Demethylcolchicine	Microtubule/Tubulin	Inflammation/Immunology
Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis .

Diallyl tetrasulfide	Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
Diallyl tetrasulfide is an orally active diallyl tetrasulfide. Diallyl tetrasulfide ameliorates cadmium-induced changes in acetylcholinesterase and adenosine triphosphatase activities as well as oxidative stress injury in the brain of rats . Diallyl tetrasulfide inhibits lipid peroxidation in rat liver microsomes . Diallyl tetrasulfide ameliorates cadmium-induced oxidative liver injury in rats . Diallyl tetrasulfide protects cells against cadmium-induced loss of cell viability, reduces apoptosis rate and ROS production. Diallyl tetrasulfide is applicable to research related to cadmium-induced neurotoxicity and cadmium-induced oxidative liver injury .

Fasiglifam hemihydrate TAK-875 hemihydrate	Free Fatty Acid Receptor	Metabolic Disease
Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC₅₀ of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury .

NIR-RED ROS-H2O2 Probe	Fluorescent Dye	Metabolic Disease
NIR-RED ROS-H2O2 Probe is a near-infrared fluorescent probe used for detecting hydrogen peroxide (H₂O₂) and featuring dual-modal fluorescence/photoacoustic imaging capabilities. NIR-RED ROS-H2O2 Probe successfully detects the upregulated fluorescence signal of H₂O₂ in HepG2 cells and a mouse liver injury model. NIR-RED ROS-H2O2 Probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .

IR-990	Fluorescent Dye	Others
IR-990 is an activatable NIR-II fluorescent probe with an acceptor-π-acceptor (A-π-A) skeleton for real-time detection of H₂O₂ in vivo. IR-990 is a powerful diagnosis of agent-induced liver injury (DILI) .

NIR-RED ATP Probe	Fluorescent Dye	Metabolic Disease
NIR-RED ATP Probe is a NIR-II fluorescent probe. NIR-RED ATP Probe exhibits high affinity and selectivity for ATP and can non-invasively and with high contrast detect changes in ATP concentration at the cellular level, with minimal interference to the abundant biomolecules within the cells. NIR-RED ATP Probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .

ALP Green	Phosphatase Fluorescent Dye	Metabolic Disease
ALP Green (Probe 4) is an amphiphilic ALP fluorescent probe (Em = 550 nm). ALP Green can be used in the research of APAP (HY-66005)-induced liver injury .

LT-630	HDAC	Inflammation/Immunology
LT-630 is a HDAC6 inhibitor. LT-630 ameliorates liver injury by reducing oxidative damage .

FXR agonist 11	FXR	Metabolic Disease
FXR agonist 11 (Compound 14) is an FXR agonist with an EC₅₀ of 1.2 μM and a maximum effect of 73.7%. FXR agonist 11 can significantly increase GSH levels in the liver and is used to study drug-induced liver injury diseases .

Praeroside IV	Others	Inflammation/Immunology
Praeroside IV can be isolated from the roots of Angelica furcijuga. Praeroside IV can be used for research of D-GalN/LPS-induced liver injury .

Cytaphat	Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
Cytaphat is a compound with hepatoprotective activity. Cytaphat has antioxidant, membrane-stabilizing and choleretic effects. Cytaphat can be used in the research of diseases such as acute toxic hepatopathy and liver injury .

TTX-P	Fluorescent Dye	Others
TTX-P is a fluorescent probe. TTX-P responds in situ to the overexpressed alkaline phosphatase (ALP) in liver, imaging of diabetic liver injury in the near-infrared second-window (NIR-II) region .

Colchiceine (Standard) O10-Demethylcolchicine (Standard)	Microtubule/Tubulin Reference Standards	Inflammation/Immunology
Colchiceine (Standard) is the analytical standard of Colchiceine. This product is intended for research and analytical applications. Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis .

Bellericagenin A	Bacterial	Infection
Bellericagenin A is a pentacyclic triterpenic acid isolated from the bark of Terminalia bellerica. Bellericagenin A exhibits antimicrobial activity. Bellericagenin A exhibits a high affinity to alcohol dehydrogenase (ADH), which has the potential for ameliorating the alcoholic liver injury .

Hepatoprotective agent-2	Apoptosis	Metabolic Disease
Hepatoprotective agent-2 (compound 2a), a 4-phenyl-tetrahydroquinoline derivative, displays a remarkable hepatoprotective effect. Hepatoprotective agent-2 has antiapoptotic activity. Hepatoprotective agent-2 notably prevents the chemically induced elevation of hepatic indicators associated with liver injury .

HSD17B13-IN-5	17β-HSD	Metabolic Disease
HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a K_i value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HSD17B13-IN-4	17β-HSD	Metabolic Disease
HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a K_i value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HSD17B13-IN-94	Estrogen Receptor/ERR 17β-HSD	Metabolic Disease
HSD17B13-IN-94 (Compound 12) is an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for Estradiol (HY-B0141). HSD17B13-IN-94 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD, NASH, or drug-induced liver injury (DILI) .

HSD17B13-IN-29	17β-HSD	Metabolic Disease
HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HSD17B13-IN-49	17β-HSD	Metabolic Disease
HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HSD17B13-IN-69	17β-HSD	Metabolic Disease
HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HSD17B13-IN-86	17β-HSD	Metabolic Disease
HSD17B13-IN-86 (Compound 188) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-86 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HSD17B13-IN-52	17β-HSD	Metabolic Disease
HSD17B13-IN-52 (Compound 84) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-52 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HSD17B13-IN-66	17β-HSD	Metabolic Disease
HSD17B13-IN-66 (Compound 146) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-66 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

Cat. No.	상품명

HY-L076

Drug-Induced Liver Injury (DILI) Compound Library

641 compounds

Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.

DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver.

MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 641 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

Cat. No.	상품명	Type

HY-D3000

NIR-RED ROS-H2O2 Probe

Fluorescent Dyes

NIR-RED ROS-H2O2 Probe is a near-infrared fluorescent probe used for detecting hydrogen peroxide (H₂O₂) and featuring dual-modal fluorescence/photoacoustic imaging capabilities. NIR-RED ROS-H2O2 Probe successfully detects the upregulated fluorescence signal of H₂O₂ in HepG2 cells and a mouse liver injury model. NIR-RED ROS-H2O2 Probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .

HY-D2999

NIR-RED ATP Probe	Fluorescent Dyes
NIR-RED ATP Probe is a NIR-II fluorescent probe. NIR-RED ATP Probe exhibits high affinity and selectivity for ATP and can non-invasively and with high contrast detect changes in ATP concentration at the cellular level, with minimal interference to the abundant biomolecules within the cells. NIR-RED ATP Probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .

HY-D3002

ONOO-/O2- tracker probe	Fluorescent Dyes
ONOO-/O2- tracker probe is a dual-responsive near-infrared fluorescent probe. ONOO-/O2- tracker probe will only emit a strong fluorescence signal when both peroxynitrite (ONOO⁻) and superoxide anion (O₂•⁻), the two key reactive oxygen/nitrogen species, are present simultaneously. ONOO-/O2- tracker probe can be used as a biomarker detection tool for drug-induced liver injury (DILI) .

HY-D3008

ALP Green	Fluorescent Dyes
ALP Green (Probe 4) is an amphiphilic ALP fluorescent probe (Em = 550 nm). ALP Green can be used in the research of APAP (HY-66005)-induced liver injury .

HY-149835

TTX-P	Fluorescent Dyes
TTX-P is a fluorescent probe. TTX-P responds in situ to the overexpressed alkaline phosphatase (ALP) in liver, imaging of diabetic liver injury in the near-infrared second-window (NIR-II) region .

HY-D3191

L&M-D-MR

Fluorescent Dyes

L&M-D-MR is a highly specific fluorescent "AND" logic probe with response moieties for leucine aminopeptidase (LAP) and monoamine oxidase (MAO). The coexistence of both LAP and MAO is required for L&M-D-MR to trigger intramolecular cyclization, release fluorophores and activate fluorescence. In the presence of only a single enzyme, L&M-D-MR generates only an extremely weak signal. L&M-D-MR enables bioimaging in living cells and mouse models, and can effectively distinguish different subtypes of liver diseases via blood samples or test strips. L&M-D-MR is widely used in studies related to liver cirrhosis, hepatitis B and drug-induced liver injury .

Cat. No.	상품명	Type

HY-Y1147

Diethyl maleate

1 Publications Verification

Maleic acid diethyl ester

Biochemical Assay Reagents

Diethyl maleate (DEM) is an orally available, effective glutathione (GSH) depletor that crosses the blood-brain barrier. Diethyl maleate covalently binds irreversibly to GSH via glutathione S-transferase with an in vitro IC50 of 0.1-0.5 mM. Diethyl maleate selectively depletes GSH in liver, lung, and brain tissues, exacerbating oxidative stress and enhancing hyperbaric oxygen toxicity. Diethyl maleate promotes precursor amino acid uptake and in turn promotes GSH synthesis by upregulating the activity of the cystine-glutamate transporter X_{O ^-}. Diethyl maleate can be used to study redox homeostasis and GSH protection mechanisms in oxidative stress-related diseases such as hyperbaric oxygen injury and metabolic diseases[1][2][3].

HY-W105505

SAMe-1,4-Butanedisulfonate	Biochemical Assay Reagents
SAMe-1,4-Butanedisulfonate, a natural compound, is a methyl donor in the central nervous system. SAMe-1,4-Butanedisulfonate has antidepressant activity. SAMe-1,4-Butanedisulfonate can be used for research of CNS disorders .

Cat. No.	상품명	Target	Research Area

HY-P1624

Teduglutide 2 Publications Verification ALX-0600	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P3211

Nangibotide Maximum Cited Publications 7 Publications Verification LR12	TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis	Cardiovascular Disease Inflammation/Immunology
Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .

HY-P3211A

Nangibotide TFA Maximum Cited Publications 7 Publications Verification LR12 TFA	TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis	Cardiovascular Disease Inflammation/Immunology
Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .

HY-P10102

Kp7-6 2 Publications Verification	Apoptosis PERK NF-κB Caspase JNK	Inflammation/Immunology Cancer
Kp7-6 is a Fas mimetic peptide and also a Fas/FasL antagonist. Kp7-6 specifically binds to Fas and FasL, disrupts receptor complexes, and blocks downstream apoptosis signaling pathways. Kp7-6 inhibits the phosphorylation of ERK1-2, induces the phosphorylation of IκBα, and activates NF-κB. Kp7-6 inhibits the activation of caspase-8, caspase-3 and JNK, and suppresses human amylin-induced β-cell apoptosis. Kp7-6 inhibits FasL-induced lymphoid cytotoxicity and apoptosis. Kp7-6 reduces local tumor FasL expression, increases CD8 ⁺Fas ⁺ T cell infiltration, and decreases tumor volume in pancreatic neuroendocrine tumor models. Kp7-6 prevents concanavalin A-induced liver injury in mice. Kp7-6 is applicable to research related to type 2 diabetes, concanavalin A-induced hepatitis and pancreatic neuroendocrine tumors .

HY-P10897

SjDX5-271	Toll-like Receptor (TLR) NF-κB	Cardiovascular Disease Inflammation/Immunology
SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury .

HY-P1624S1

Teduglutide-Leu(13C6,15N) sodium ALX-0600-Leu(13C6,15N) sodium	Isotope-Labeled Compounds Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide-Leu( ¹³C₆, ¹⁵N) (ALX-0600-Leu( ¹³C₆, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P1624A

Teduglutide TFA ALX-0600 TFA	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P10897A

SjDX5-271v	Toll-like Receptor (TLR) NF-κB	Cardiovascular Disease Inflammation/Immunology
SjDX5-271v is a negative control of SjDX5-271 (HY-P10897). SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury .

HY-P3148

Astin B	p62 Atg8/LC3 Apoptosis Autophagy Reactive Oxygen Species (ROS) JNK Bcl-2 Family Caspase	Metabolic Disease
Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression .

HY-P1624S

Teduglutide-Ala(13C3,15N) sodium ALX-0600-Ala(13C3,15N) sodium	Isotope-Labeled Compounds Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide-Ala( ¹³C₃, ¹⁵N) (ALX-0600-Ala( ¹³C₃, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

Cat. No.	상품명	Target	Research Area	Image

HY-P990116

Anti-Mouse osteopontin/SPP1 Antibody (103D6)	Osteopontin	Inflammation/Immunology
Anti-Mouse osteopontin/SPP1 Antibody (103D6) is a mouse-derived anti-mouse osteopontin/SPP1 IgG2c κ type antibody inhibitor. Anti-Mouse osteopontin/SPP1 Antibody (103D6) increases cytotoxic T lymphocyte lytic activity and suppresses colon tumor growth. Anti-Mouse osteopontin/SPP1 Antibody (103D6) ameliorates liver injury in common bile duct ligation (CBDL)-induced primary sclerosing cholangitis mice models .

HY-P992072

Anti-Human/Mouse CD95 Antibody (HFE7A)	Apoptosis Caspase	Metabolic Disease
Anti-Human/Mouse CD95 Antibody (HFE7A) is an antibody targeting human/mouse Fas (CD95), with a K_d of 1.6 nM in mice. Anti-Human/Mouse CD95 Antibody (HFE7A) modulates the Fas-mediated apoptotic signaling pathway without blocking the binding of Jo2 to Fas. Anti-Human/Mouse CD95 Antibody (HFE7A) inhibits Jo2-induced caspase activation, mitochondrial depolarization, hepatocyte death and apoptosis. Anti-Human/Mouse CD95 Antibody (HFE7A) protects BALB/c mice against Jo2-induced acute liver injury and reduces Jo2-associated elevation of serum transaminase levels. Anti-Human/Mouse CD95 Antibody (HFE7A) can be used in studies related to liver injury. For isotype control, refer to Mouse IgG1 kappa, Isotype Control (HY-P99977) .

Cat. No.	상품명	Chemical Structure

HY-110228

Metformin-d6 hydrochloride

Metformin-d₆ hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-B0627S

Metformin-d6

Metformin-d₆ (1,1-Dimethylbiguanide-d₆) is a deuterated labeled Metformin (HY-B0627). Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-W012790S

Sodium 2-hydroxybutanoate-d3

Sodium 2-hydroxybutanoate-d₃ is the deuterium labeled Sodium 2-hydroxybutanoate . Sodium 2-hydroxybutanoate (2-Hydroxybutyric acid sodium) is converted from 2-Aminobutyric acid, with 2-oxobutyric acid as an intermediate metabolite . Sodium 2-hydroxybutanoate is a potential biomarker for type 2 diabetes and preeclampsia . Sodium 2-hydroxybutanoate prevents the acetaminophen (AP)-induced liver injury .

HY-P1624S1

Teduglutide-Leu(13C6,15N) sodium

Teduglutide-Leu( ¹³C₆, ¹⁵N) (ALX-0600-Leu( ¹³C₆, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-13315S1

Montelukast-d6 sodium
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage .

HY-42682S1

D(+)-Galactosamine-13C hydrochloride
D(+)-Galactosamine- ¹³C (hydrochloride) is the ¹³C labeled D(+)-Galactosamine hydrochloride. D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and

HY-B0627S1

Metformin-13C2 hydrochloride

Metformin- ¹³C₂ (1,1-Dimethylbiguanide- ¹³C₂) hydrochloride is the ¹³C-labeled Metformin hydrochloride (HY-17471A). Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-163253S

HSD17B13-IN-56-d3
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-109120S

Odevixibat-d5
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-13315S

Montelukast-d6
Montelukast-d₆ is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage .

HY-B0149S3

Tranexamic acid-13C2,15N
Tranexamic acid- ¹³C₂, ¹⁵N (Cyclocapron- ¹³C₂, ¹⁵N) is the ¹³C₂ and ¹⁵N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .

HY-113486S1

lathosterol-d7
lathosterol-d₇ is deuterium labeled Lathosterol (HY-113486). Lathosterol is a plant sterol and cholesterol-like molecule. Lathosterol increases antioxidant enzymes (such as SOD, CAT, and GSH) and decreases LDH. Lathosterol has a hepatoprotective effect on mice with acetaminophen (HY-66005)-induced liver injury ^{^.}

HY-163263S1

HSD17B13-IN-80-d2

HSD17B13-IN-80-d₂ (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-117660S

Lincomycin-d3

Lincomycin-d₃ (U-10149-d₃) is the deuterium labeled Lincomycin. Lincomycin is an orally active lincosamide antibiotic. Lincomycin binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice.

HY-W778179

Benoxaprofen-13C,d3

Benoxaprofen- ¹³C, d₃ is the ¹³C-labeled Benoxaprofen (HY-13568). Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .

HY-P1624S

Teduglutide-Ala(13C3,15N) sodium

Teduglutide-Ala( ¹³C₃, ¹⁵N) (ALX-0600-Ala( ¹³C₃, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-B1120S

Temephos-d12

Temephos-d₁₂ is the deuterium labeled Temephos. Temephos (Temefos) is an orally active, blood-brain barrier-permeable organophosphate insecticide and AChE inhibitor. By irreversibly inhibiting AChE to induce cholinergic overactivation, Temephos effectively blocks larval development of Aedes aegypti (yellow fever mosquito) and Aedes albopictus (Asian tiger mosquito), and is commonly used in studies related to Dengue Virus, Zika Virus and other relevant pathogens. Temephos exhibits genotoxicity and neurodevelopmental toxicity, and may also cause liver injury, reproductive system abnormalities and cholinergic poisoning symptoms in mammals. Temephos tends to accumulate in adipose tissues and aquatic organisms, and is excreted via feces after metabolism through oxidation and hydrolysis. Note that CYP-mediated metabolic detoxification may reduce the actual larvicidal efficacy of Temephos against some mosquito species. Temephos can be used in research related to dengue fever, Zika virus disease, chikungunya and dracunculiasis .

Cat. No.	상품명		Classification

HY-B0892

Benzyl alcohol 3 Publications Verification Benzenemethanol		Preservatives Solvents
Benzyl alcohol is an aromatic alcohol, a colorless liquid with a mild aromatic odor. Benzyl alcohol is an inhibitor of P450 enzyme. Benzyl alcohol mediated Toll-Like Receptor 4 to reduce the inflammatory response of liver injury in mice .

HY-177809

aptTNF-α sodium		Aptamers
aptTNF-α sodium is a TNF-α-targeting aptamer that has tissue protective effect and systemic anti-inflammatory effect upon acute tissue injury using the mouse acute lung injury (ALI) and acute liver failure (ALF) models.

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

Liver injury

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products